Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin.
Amelia L QuinnOlivia M DeanChristopher G DaveyMelissa KerrSusy M HarriganSue M CottonAndrew M ChanenSeetal DoddAswin RatheeshG Paul AmmingerMark PhelanAmber WilliamsAndrew MackinnonFrancesco GiorlandoShelley BairdSimon RiceMelissa O'SheaMiriam R SchäferEdward MullenSarah Elisabeth HetrickPatrick McGorryMichael BerkPublished in: Early intervention in psychiatry (2015)
Timely and targeted intervention for youth MDD is crucial. Given the paucity of new agents to treat youth MDD, adjunctive trials are not only pragmatic and 'real-world', but additionally aim to target shortfalls in conventional medications. This study has the potential to first provide two new adjunctive treatment options for youth MDD; aspirin and rosuvastatin. Second, this study will serve as proof of principle of the role of inflammation in MDD.
Keyphrases
- major depressive disorder
- mental health
- physical activity
- young adults
- low dose
- randomized controlled trial
- anti inflammatory
- cardiovascular events
- clinical trial
- depressive symptoms
- study protocol
- antiplatelet therapy
- squamous cell carcinoma
- placebo controlled
- coronary artery disease
- drug delivery
- cardiovascular disease
- type diabetes
- acute coronary syndrome
- climate change
- cancer therapy
- risk assessment
- double blind
- percutaneous coronary intervention
- soft tissue
- phase ii
- rectal cancer
- phase ii study